Methanone, [2-[(2-aminophenyl)thio]phenyl][4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-

Catalog No. :
ACWDKR593
CAS No. :
848814-27-7
Molecular Formula :
C21H27N3O3S
Molecular Weight :
401.53

IUPAC Name:(2-((2-aminophenyl)thio)phenyl)(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)methanone

Methanone, [2-[(2-aminophenyl)thio]phenyl][4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]- structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMethanone, [2-[(2-aminophenyl)thio]phenyl][4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-
IUPAC Name(2-((2-aminophenyl)thio)phenyl)(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)methanone
Molecular FormulaC21H27N3O3S
Molecular Weight401.53
SMILESNC1=C(C=CC=C1)SC2=C(C(N3CCN(CCOCCO)CC3)=O)C=CC=C2
InChI KeyJPBFGXQLPAVCOY-UHFFFAOYSA-N
Synonym2-(2-amino-phenylsulfanyl)-phenyl-{4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl}methanone;Quetiapine EP Impurity F;Quetiapine Impurity F;Quetiapine Impurity 26;(2-((2-Aminophenyl)thio)phenyl)(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)methanone;Quetiapine Impurity 23(Quetiapine EP Impurity F);Quetiapine Impurity F HCl;Methanone, [2-[(2-aminophenyl)thio]phenyl][4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-
CAS No.848814-27-7

Synthetic Route by SureRoute

1. ACWDKR593 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACWDKR593 route product structure diagram
    ACWDKR593848814-27-7
Inquiry

2. ACWDKR593 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLIPG589 route compound structure diagram
    ACLIPG58954920-98-8 In Stock
  2. Plus
  3. ACKTJD609 route compound structure diagram
    ACKTJD60913349-82-1 In Stock
  4. Then
  5. ACWDKR593 route product structure diagram
    ACWDKR593848814-27-7
Inquiry

Comments (0)